Source comparison
MOTS-c Half-Life: Research Peptides Comparison
MOTS-c 1.5–2 hours 24–48 hours AMPK activation, nuclear gene regulation, mitochondrial biogenesis Once daily Ideal for sustained metabolic studies. Short clearance but long signaling duration allows daily dosing without accumulation risk Humanin 30–45 minutes
This comparison does not assign a generated winner or score.
- MOTS-c
- 1.5–2 hours
- 24–48 hours
- AMPK activation, nuclear gene regulation, mitochondrial biogenesis
- Once daily
- Ideal for sustained metabolic studies. Short clearance but long signaling duration allows daily dosing without accumulation risk
- Humanin
- 30–45 minutes
- 12–24 hours
- Neuroprotection via STAT3, anti-apoptotic signaling
- 1–2× daily
- Requires more frequent dosing than MOTS-c due to shorter effect window; often paired with MOTS-c in aging studies
- BPC-157
- 4–6 hours
- 24–72 hours
- Angiogenesis, VEGF upregulation, tissue repair signaling
- Once daily or every 48h
- Longer plasma stability but similar downstream duration to MOTS-c. Injury repair protocols can stretch dosing intervals
- AOD-9604
- 2–3 hours
- 12–18 hours
- Lipolysis via β3-adrenergic receptor, no GH receptor binding
- Shorter biological window than MOTS-c; twice-daily dosing common in fat metabolism research
- SS-31 (Elamipretide)
- 2–4 hours
- 48–72 hours
- Cardiolipin stabilization, mitochondrial membrane protection
- Similar to MOTS-c in half-life/effect duration gap. Once-daily dosing sufficient for mitochondrial protection studies
- The comparison shows MOTS-c fits within a broader pattern of mitochondrial-targeting peptides: short plasma residence, long functional duration. Peptides that work via receptor agonism (like many GLP-1 analogs) require sustained plasma levels; peptides that trigger intracellular signaling cascades do not.